Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics
Author(s): Jason H. Gill, Kimberly L. Rockley, Carol De Santis, Asma K. Mohamed
Keywords: Cancer therapy; Cardioncology; Cardiovascular toxicity; Vascular disrupting agents.
Abstract
Destruction of the established tumour vasculature by a class of compound termed Vascular Disrupting Agents (VDAs) is showing considerable promise as a viable approach for the management of solid tumours. VDAs induce a rapid shutdown and collapse of tumour blood vessels, leading to ischaemia and consequent necrosis of the tumour mass. Their efficacy is hindered by the persistence of a viable rim of tumour cells, supported by the peripheral normal vasculature, necessitating their co-administration with additional chemotherapeutics for maximal therapeutic benefit. However, a major limitation for the use of many cancer therapeutics is the development of life-threatening cardiovascular toxicities, with significant consequences for treatment response and the patient’s quality of life. The aim of this review is to outline VDAs as a cancer therapeutic approach and define the mechanistic basis of cardiovascular toxicities of current chemotherapeutics, with the overall objective of discussing whether VDA combinations with specific chemotherapeutic classes would be good or bad in terms of cardiovascular toxicity.
Source
References
E.M. Aboubakr et al. Enhanced anticancer effect of combretastatin A-4 phosphate when combined with vincristine in the treatment of hepatocellular carcinoma Biomedicine & Pharmacotherapy (2017)
C.L. Airey et al. Etoposide-related myocardial infarction Clinical Oncology (Royal College of Radiologists) (1995)
R.S. Alameddine et al. Cardiac and vascular toxicities of angiogenesis inhibitors: The other side of the coin Critical Reviews in Oncology/Hematology (2015)
R. Altena et al. Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer Annals of Oncology (2011)
P. Baluk et al. Cellular abnormalities of blood vessels as targets in cancer Current Opinion in Genetics & Development (2005)
D.C. Blakey et al. ZD6126: a novel small molecule vascular targeting agent International Journal of Radiation Oncology, Biology, Physics (2002)
J.Y. Blay et al. Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet Oncology (2015)
A.C. Cameron et al. Vascular complications of cancer chemotherapy The Canadian Journal of Cardiology (2016)
D. Cappetta et al. Doxorubicin targets multiple players: A new view of an old problem Pharmacological Research (2018)
D.M. Chase et al. The development and use of vascular targeted therapy in ovarian cancer Gynecologic Oncology (2017)
T.F. Chu et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet (2007)
G. Curigliano et al. Cardiac toxicity from systemic cancer therapy: a comprehensive review Progress in Cardiovascular Diseases (2010)
J.L. Delgado et al. Topoisomerases as anticancer targets The Biochemical Journal (2018)
I. Depetris et al. Fluoropyrimidine-induced cardiotoxicity Critical Reviews in Oncology/Hematology (2018)
E.I. Deryugina et al. Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature Matrix Biology (2015)
G. Di Lorenzo et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis Annals of Oncology (2009)
C.G. van Dijk et al. The complex mural cell: Pericyte function in health and disease International Journal of Cardiology (2015)
H. Gelderblom et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation European Journal of Cancer (2001)
J.A. Gietema et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer Lancet (2000)
A. Greystoke et al. A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours Annals of Oncology (2006)
Y.J. Ho et al. Current progress in antivascular tumor therapy Drug Discovery Today (2017)
K. Jaroch et al. Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status Pharmacological Reports (2016)
Q. Ke et al. Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats Vascular Pharmacology (2009)
Q. Ke et al. Exaggerated hypertensive response to combretastatin A-4 phosphate in hypertensive rats: Effective pharmacological inhibition by diltiazem Vascular Pharmacology (2015)
J.W. Lippert Vascular disrupting agents Bioorganic & Medicinal Chemistry (2007)
M. Lotrionte et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity The American Journal of Cardiology (2013)
H.L. Anderson et al. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate Journal of Clinical Oncology (2003)
J.M. Atkinson et al. Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases Cancer Research (2010)
C. Bagnes et al. Antineoplastic chemotherapy induced QTc prolongation Current Drug Safety (2010)
R. Bahleda et al. Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors Investigational New Drugs (2014)
K.D. Barlow et al. Pericytes on the tumor vasculature: jekyll or hyde? Cancer Microenvironment (2013)
L.V. Beerepoot et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors Journal of Clinical Oncology (2006)
A.M. Bellinger et al. Cardio-oncology: How new targeted cancer therapies and precision medicine can inform cardiovascular discovery Circulation (2015)
I. Brana et al. Cardiotoxicity Annals of Oncology (2010)
M. Burge et al. Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent Investigational New Drugs (2013)
D. Cappetta et al. Oxidative stress and cellular response to doxorubicin: A common factor in the complex milieu of anthracycline cardiotoxicity Oxidative Medicine and Cellular Longevity (2017)
D. Cardinale et al. Curing cancer, saving the heart: A challenge that cardioncology should not miss Current Cardiology Reports (2016)
M.C. Chamberlain et al. A phase 2 trial of verubulin for recurrent glioblastoma: A prospective study by the Brain Tumor Investigational Consortium (BTIC) Journal of Neuro-Oncology (2014)
A. Chauhan et al. A phase 1 study of fosbretabulin in combination with everolimus in neuroendocrine tumors (Grades 1-3) that have progressed after at least one prior regimen for metastatic disease Pancreas (2018)
A. Chauhan et al. A phase I/II study of fosbretabulin in combination with everolimus in neuroendocrine tumors that have progressed after at least one prior regimen for metastatic disease Journal of Clinical Oncology (2018)
M. Chen et al. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents The Journal of Clinical Investigation (2017)
C. Coderch et al. Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids Anti-Cancer Agents in Medicinal Chemistry (2012)
C.R. Cogle et al. A phase i study of the vascular disrupting combretastatin, OXi4503, in patients with relapsed and refractory acute myeloid leukemia (AML) and Myelodysplastic Syndromes (MDS) Blood (2012)
I. Collins et al. New approaches to molecular cancer therapeutics Nature Chemical Biology (2006)
G.D. Conte et al. A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors (NCT01193595) Journal of Clinical Oncology (2012)
M.M. Cooney et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer Clinical Cancer Research (2004)
L. Cosmai et al. Renal toxicity of anticancer agents targeting HER2 and EGFR Journal of Nephrology (2015) G. Curigliano et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines Annals of Oncology (2012)
R.M. Damiani et al. Pathways of cardiac toxicity: Comparison between chemotherapeutic drugs doxorubicin and mitoxantrone Archives of Toxicology (2016)
A. Dorigo et al. Lomustine, etoposide, methotrexate and prednisone (LEMP) therapy for relapsed and refractory non-Hodgkin’s lymphoma European Journal of Haematology (1993)
There are more references available in the full text version of this article.